Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Placebo-Controlled, Single Dose, Dose Escalation (Part A) and a Placebo- and Positive-Controlled Study of the Effect on the Electrocardiographic QT Interval of a Single Dose (Part B) of LY3009104 in Healthy Subjects

NCT01536951 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT01536951
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01536951 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Placebo-Controlled, Single Dose, Dose Escalation (Part A) and a Placebo- and Positive-Controlled Study of the Effect on the Electrocardiographic QT Interval of a Single Dose (Part B) of LY3009104 in Healthy Subjects
Lead sponsor
Eli Lilly and Company
Phase
Phase 1
Overall status
Completed
Start date
February 29, 2012
Completion date
May 31, 2013
Enrollment
62 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy participants